Absolute risk of venous thromboembolism per 10 000 by exposure to urate-lowering therapy
| Variable | N | Person-years | Rate (95% CI) | IRR (95% CI) | IRR (95% CI) adjusted* |
|---|---|---|---|---|---|
| All periods | |||||
| Not exposed to ULT | 268 | 66 168 | 40.5 (35.9–45.7) | 1.00 | 1.00 |
| Exposed to ULT | 363 | 80 798 | 44.9 (39.7–48.5) | 1.10 (0.95–1.30) | 1.04 (0.89–1.23) |
Note: CI = confidence interval, IRR = incidence rate ratio, ULT = urate-lowering therapy.
↵* Adjusted for age, gender, Charlson index calendar year, smoking status, hospital admission, deprivation, gout duration, hypertension, diabetes, acetylsalicylic acid use, thiazide use, alcohol consumption and body mass index.